Australia - inglese - Department of Health (Therapeutic Goods Administration)

australia cobayer health food co pty ltd - borax,colecalciferol,cupric sulfate pentahydrate,curcuma longa,glucosamine sulfate potassium chloride,manganese amino acid chelate,selenomethionine,shark chondroitin sulfate,salix alba -

Stati Uniti - inglese - NLM (National Library of Medicine)

advanced healthcare solutions - potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), chaste tree (unii: 433osf3u8a) (chaste tree - unii:433osf3u8a), chelidonium majus (unii: 7e889u5rnn) (chelidonium majus - unii:7e889u5rnn), fucus vesiculosus (unii: 535g2abx9m) (fucus vesiculosus - unii:535g2abx9m), lycopodium clavatum spore (unii: c88x29y479) (lycopodium clavatum spore - unii:c88x29y479), thuja occidentalis leafy twig (unii - potassium phosphate, dibasic 3 [hp_x] in 1 ml - supports metabolism. supports metabolism.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

neat feat warehousing pty ltd - salix alba, quantity: 50 mg/g (equivalent: salix alba, qty 50 mg/g); thuja occidentalis, quantity: 20 mg/g; filipendula ulmaria, quantity: 50 mg/g (equivalent: filipendula ulmaria, qty 50 mg/g; equivalent: methyl salicylate, qty 1 mg/g) - gel - excipient ingredients: acetic acid; apple cider vinegar; ethanol; lactic acid; potassium sorbate; glycerol; purified water; xanthan gum - helps reduce/relieve warts

Stati Uniti - inglese - NLM (National Library of Medicine)

the hain celestial group, inc. - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - use - for the treatment of acne - apply to freshly cleansed face morning and evening - for the best results, use after alba botanica natural acnedote deep clean astringent acne treatment

Stati Uniti - inglese - NLM (National Library of Medicine)

biolyte laboratories, llc - salix alba bark (unii: 205mxs71h7) (salix alba bark - unii:205mxs71h7), stellaria media (unii: 2h03479qvr) (stellaria media - unii:2h03479qvr), daphne mezereum bark (unii: x2n6e405gv) (daphne mezereum bark - unii:x2n6e405gv), urtica urens (unii: ihn2nq5of9) (urtica urens - unii:ihn2nq5of9), althaea officinalis root (unii: trw2fuf47h) (althaea officinalis root - unii:trw2fuf47h), hamamelis virginiana root bark/stem bark (unii: t7s323pkjs) (hamamelis virginiana root bark/stem bark - unii:t7s323pkjs), ho - promotes wound healing topical analgesics reduces itching anti-inflammatory helps reduce potential infection in minor cuts, scrapes and abrasions. for the temporary relief of itchiness and soreness. promotoes wound healing. indications are based on homeopathic materia medica, not clinical tests.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

alw health pty ltd - curcuma longa, quantity: 200 mg (equivalent: curcuma longa, qty 4 g; equivalent: curcumin, qty 150 mg); harpagophytum procumbens, quantity: 100 mg (equivalent: harpagophytum procumbens, qty 4.8 g); boswellia serrata, quantity: 125 mg (equivalent: boswellia serrata, qty 1.75 g); salix alba, quantity: 120 mg (equivalent: salix alba, qty 12 g); piper nigrum, quantity: 1.58 mg (equivalent: piper nigrum, qty 25.28 mg) - capsule, hard - excipient ingredients: maltodextrin; stearic acid; colloidal anhydrous silica; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum - anti-inflammatory/relieve inflammation ; analgesic/anodyne/relieve pain ; decrease/reduce/relieve mild joint aches and pains ; decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis (linked indication:decrease/reduce/relieve mild joint aches and pains; decrease/reduce/relieve mild joint pain/soreness); decrease/reduce/relieve mild joint pain/soreness

Stati Uniti - inglese - NLM (National Library of Medicine)

merck sharp & dohme corp. - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - furosemide 50 mg - a diuretic-saluretic for prompt relief of edema. dogs and cats salix® is an effective diuretic possessing a wide therapeutic range. pharmacologically it promotes the rapid removal of abnormally retained extracellular fluids. the rationale for the efficacious use of diuretic therapy is determined by the clinical pathology producing the edema. salix® is indicated for the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema. the continued use of heart stimulants, such as digitalis or its glycosides is indicated in cases of edema involving cardiac insufficiency. salix® is a highly effective diuretic-saluretic which if given in excessive amounts may result in dehydration and electrolyte imbalance. therefore, the dosage and schedule may have to be adjusted to the patient's needs. the animal should be observed for early signs of electrolyte imbalance, and corrective measures administered. early signs of electrolyte imbalance are: increased thirst, lethargy, drowsiness or restlessness, fatigue, oliguria, gastro-intestinal disturbances and tachycardia. special attention should be given to potassium levels. salix® may lower serum calcium levels and cause tetany in rare cases of animals having an existing hypocalcemic tendency. although diabetes mellitus is a rarely reported disease in animals, active or latent diabetes mellitus may on rare occasions be exacerbated by salix® . while it has not been reported in animals the use of high doses of salicylates, as in rheumatic diseases, in conjunction with salix® may result in salicylate toxicity because of competition for renal excretory sites. transient loss of auditory capacity has been experimentally produced in cats following intravenous injection of excessive doses of salix® at a very rapid rate. electrolyte balance should be monitored prior to surgery in patients receiving salix® . imbalances must be corrected by administration of suitable fluid therapy. salix® is contraindicated in anuria. therapy should be discontinued in cases of progressive renal disease if increasing azotemia and oliguria occur during the treatment. sudden alterations of fluid and electrolyte imbalance in an animal with cirrhosis may precipitate hepatic coma, therefore observation during period of therapy is necessary. in hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved or corrected. potassium supplementation may be necessary in cases routinely treated with potassium-depleting steroids.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

export corporation australia pty ltd - arctostaphylos uva-ursi,citrus aurantium,caffeine,camellia sinensis,capsicum annuum,choline bitartrate,chromium picolinate,coffea arabica,coffea canephora,inositol,juniperus communis,levocarnitine,pelargonium graveolens,piper nigrum,plectranthus barbatus,potassium aspartate,salix alba,taraxacum officinale,theobroma cacao -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmacare laboratories pty ltd - salix alba,sambucus nigra -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

phytologic holdings pty ltd - ascorbic acid,apium graveolens,prunus cerasus,salix alba -